3M licenses vaccine adjuvants to VaxInnate
This article was originally published in Scrip
3M has licensed its small-molecule toll-like receptor (TLR) agonists to VaxInnate for use as vaccine adjuvants. It said that data suggested that they could enhance vaccine potency.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.